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Summary
Objective: To analyze the costs of human immunodeficiency virus (HIV) outpatient treatment for indi-
viduals with different CD4 cell counts in the Brazilian public health system, and to compare to costs in 
other national health systems. Methods: A retrospective survey was conducted in five public outpatient 
clinics of the Brazilian national HIV program in the city of São Paulo. Data on healthcare services pro-
vided for a period of one year of HIV outpatient treatment were gathered from randomly selected medi-
cal records. Prices of inputs used were obtained through market research and public sector databases. 
Information on costs of HIV outpatient treatment in other national health systems were gathered from 
the literature. Annual costs of HIV outpatient treatment from each country were converted into 2010 
U.S. dollars. Results: Annual cost of HIV outpatient treatment for the Brazilian national public program 
was US$ 2,572.92 in 2006 in São Paulo, ranging from US$ 1,726.19 for patients with CD4 cell count 
> 500 to US$ 3,693.28 for patients with 51 ≤ CD4 cell count < 200. Antiretrovirals (ARVs) represented 
approximately 62.0% of annual HIV outpatient costs. Comparing among different health systems during 
the same period, HIV outpatient treatment presented higher costs in countries where HIV treatment is 
provided by the private sector. Conclusion: The main cost drivers of HIV outpatient treatment in differ-
ent health systems were: ARVs, other medications, health professional services, and diagnostic exams. 
Nevertheless, the magnitude of cost drivers varied among HIV outpatient treatment programs due to 
health system efficiency. The data presented may be a valuable tool for public policy evaluation of HIV 
treatment programs worldwide.
Keywords: HIV; antiretroviral therapy; highly active; costs and cost analysis; CD4 lymphocyte count; 
health policy.
©2012 Elsevier Editora Ltda. All rights reserved. 
reSumo
Análise comparativa dos custos ambulatoriais em programas de 
tratamento de pacientes HIV
Objetivo: Analisar custos de tratamento ambulatorial de pacientes portadores do vírus da imunodefi-
ciência humana (HIV) com diferentes níveis de CD4 no sistema público de saúde brasileiro e compa-
rar aos custos de outros sistemas de saúde. Métodos: Foi conduzida pesquisa retrospectiva em cinco 
ambulatórios especializados do programa DST/AIDS no município de São Paulo. Dados referentes à 
assistência ambulatorial para tratamento de pacientes HIV durante um ano foram obtidos em prontuá-
rios médicos selecionados aleatoriamente. Preços dos recursos utilizados foram obtidos via pesquisa de 
mercado e bancos de dados do setor público. Informações sobre custos do tratamento ambulatorial de 
pacientes HIV em outros sistemas de saúde foram obtidos na literatura. Os custos anuais de tratamento 
ambulatorial de pacientes HIV em cada país foram convertidos em dólares norte-americanos no ano base 
2010. Resultados: O custo anual de tratamento ambulatorial para pacientes HIV no programa público 
nacional foi US$ 2.572,92 em 2006 no município de São Paulo, variando entre US$ 1.726,19 para pacien-
tes com CD4 > 500 e US$ 3.693,28 para pacientes com 51 ≤ CD4 < 200. Medicamentos antirretrovirais 
(ARVs) representaram aproximadamente 62,0% dos custos de tratamento ambulatorial de pacientes HIV. 
Comparando-se custos entre diferentes sistemas de saúde no mesmo período, o tratamento ambulatorial 
de pacientes HIV apresentou custos superiores nos países onde a provisão do tratamento é realizada pelo 
setor privado. Conclusão: Os principais determinantes dos custos de tratamento ambulatorial de pacien-
tes HIV são: medicamentos ARVs, outros medicamentos, profissionais de saúde e exames diagnósticos. 
No entanto, a magnitude de participação dos determinantes de custos nos programas de tratamento 
ambulatorial de pacientes HIV varia em decorrência da eficiência do sistema de saúde. Os dados apresen-
tados constituem importante instrumento para avaliação de políticas públicas de saúde relacionadas ao 
tratamento de pacientes HIV mundialmente.
Unitermos: HIV; terapia antirretroviral de alta atividade; custos e análise de custos; contagem de linfócito 
CD4; política de saúde.
©2012 Elsevier Editora Ltda. Todos os direitos reservados.
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IntroductIon
Highly active antiretroviral therapy (HAART), adopted 
in 1996, combines antiretroviral drugs (ARVs) to reduce 
morbimortality rates among human immunodeficiency 
virus (HIV) patients, resulting in prolonged life expectan-
cy1-5 and increasing treatment costs.
Studies on costs of HIV treatment are usually per-
formed through gross-costing techniques6-11, analyzing 
specific healthcare expenditures12-19, using private perspec-
tive20-24 or exclusively using the costs for ARV provision25-29; 
all of which report general trends of HIV treatment costs.
Although there is a general consensus on the consid-
erable share of costs due to ARVs6-24,30, there is still lack 
of evidence on the major cost drivers of HIV outpatient 
treatment for individuals in different categories of CD4 
cell count, particularly regarding nationwide publicly-
financed HIV treatment programs, such as that of Brazil.
The Brazilian public program for HIV treatment was 
initiated in 1996 through ARVs distribution, prevention 
campaigns, and a healthcare program for sexually trans-
mitted diseases (STD). In 2006, the program reached 
180,000 individuals for HIV treatment within public 
health system. Currently, the Brazilian STD/ acquired 
immunodeficiency syndrome (AIDS) program provides 
inpatient and outpatient HIV treatment, including distri-
bution of 17 HAART drugs31,32.
According to Teixeira et al.5, the program resulted in 
decreased morbimortality and hospitalization rates; how-
ever, it also increased the demand for outpatient services 
and should continuously increase government expendi-
tures due to the HIV incidence of approximately 20,000 
cases per year31,32.
Investigation on the cost composition of the Brazilian 
HIV program seems necessary to promote long-term pub-
lic policy sustainability. Considering that usually there are 
data limitations to provide guidance for government deci-
sions, this article seeks to offer evidence to contribute to 
strategic planning of public policies by analyzing the costs 
of HIV outpatient treatment for individuals with different 
CD4 cell counts within the Brazilian public program.
methodS
CharaCteriStiCS oF the BraziliaN StD/aiDS prograM
The analysis was based on a retrospective survey conduct-
ed in five public outpatient clinics in São Paulo, Brazil. The 
municipal branch of the Brazilian STD/AIDS program in 
São Paulo, known as the Programa Municipal DST/AIDS 
de São Paulo (PMDASP), consists of 15 clinics for outpa-
tient treatment, three diagnostic facilities, and one admin-
istrative headquarters.
A micro-costing technique was used to perform costs 
estimates of HIV outpatient treatment for individuals with 
different CD4 cell counts within the program; based on 
identification, measurement, and valuation of resources 
required to provide the healthcare services demanded33, 
from the public provider perspective.
The Brazilian STD/AIDS program is considered a mul-
tiservice unit that provides HIV and STD outpatient treat-
ments, HIV/STD diagnoses, and HIV/STD prevention 
activities. Therefore, the program requires sets of specific 
resources to provide healthcare services (healthcare-related 
inputs), and, additionally, a set of unspecific resources shared 
among several activities (technical-administrative inputs).
Implementation of the micro-costing technique to per-
form the analysis of costs derived from HIV outpatient 
treatment in the program encompassed three stages:
1. Identification and measurement of specific resourc-
es necessary to provide HIV outpatient treatment, 
through inventory of medical procedures per-
formed in a sample of patients during 2006, in order 
to estimate the technical coefficients of the inputs;
2. Identification and measurement of unspecific re-
sources necessary to support HIV outpatient treat-
ment, via assessment of infrastructure and of the 
administrative sector within the program, and esti-
mation of an overhead allocation factor;
3. Calculation of costs due to HIV outpatient treat-
ment, through valuation of resources required using 
applicable prices and technical coefficients of inputs 
or overhead allocation factor, followed by addition 
of values and further data processing to account for 
inflation and exchange rates.
iNveNtory oF MeDiCal proCeDureS
Sample
Sample size estimate was based on a population of 11,373 
(67.7%) patients with CD4 cell count < 1,000 cells per µL 
at the beginning of the research in 2006, considering that 
CD4 cell count is usually adopted as a health status marker 
for HIV patients.
A two-stage sampling process was performed in order 
to assure representativeness. In the first stage, five settings 
of the program were selected using a stratified purposive 
sampling method, in order to represent the variability of 
socio-demographic conditions in five different regions of 
São Paulo. Distribution of patients according to CD4 cell 
count within each of the 15 clinical settings was tested, in 
order to verify similarity in relation to the distribution of 
CD4 cell count in the program.
In the second stage, medical charts in each clinical set-
ting were stratified according to CD4 cell count. A sample 
of 20 medical charts from each CD4 cell count stratum was 
randomly selected from each clinical setting; including a 
30% projected rate of losses to follow-up due to abandon-
ment of treatment, incomplete information, lost medical 
records, and other possible problems.
561_567_12_171_Comparative.indd   562 28/09/12   11:20
A compArAtive AnAlysis of outpAtient costs in Hiv treAtment progrAms
563Rev Assoc Med Bras 2012; 58(5):561-567
Data on 441 (88.2%) medical charts were collected, 
mainly due to problems in the database from one of the 
selected clinical settings. Information provided in 370 
(74.0%) medical charts was properly completed during 
2006. Primary data analysis resulted in 352 (70.4%) pa-
tients in continuous HIV outpatient treatment during 
2006. Mean and variance tests were performed in order 
to assure sample representativeness, confirming the sim-
ilarity hypothesis.
Inclusion criteria were: medical charts of individu-
als in continuous HIV outpatient treatment during 2006, 
including one CD4 cell count at the beginning of the pe-
riod and complete information on healthcare services 
provided. Exclusion criteria were: medical record in-
complete or lost, patient’s death in 2006, CD4 cell count 
< 1,000, and abandonment or irregularity in HIV treat-
ment (considering the registry of ARV withdrawals). 
The study was approved by the Ethical Committee of 
the Municipal Secretary of Health of São Paulo (Process 
0135.0.162.000-06).
Technical coefficienTS of inpuTS
Healthcare services provided during one year of HIV 
outpatient treatment were registered in a questionnaire 
containing nine sections: 1) socioeconomic data; 2) ARV 
drugs prescription; 3) other medication prescription; 4) 
vaccines; 5) diagnostic exams, CD4 cell count, and viral 
load; 6) other exams; 7) health procedures performed; 8) 
dental treatments; and 9) other information.
Health professionals were trained to complete the 
questionnaire, in order to assure quality and standard-
ization in data collection. Healthcare services registered 
in patients’ charts during 2006 were recorded in a single 
database and summarized as a set of medical procedures 
and medication annually supplied for integral medical 
assistance of HIV outpatient treatment.
Each medical procedure was split into the set of re-
sources (e.g. needle, syringe, nurse time, and other) 
required to perform the health service, according to the 
technical coefficients of inputs reported in the medical 
literature.
Certain medical procedures (vaccination and medi-
cation withdrawal) and exams (diagnoses) presented in-
sufficient evidence in the literature to support estimates 
of technical coefficients of inputs; therefore, two strate-
gies were adopted. In the first case, a focus group com-
posed of health professionals collaborated to complete 
detailed information on technical coefficients of inputs 
for medical procedures. In the second case, the three 
dedicated diagnosis facilities within the HIV treatment 
program provided the accounting data necessary to per-
form estimates of the economic costs of each exam.
aSSeSSMeNt oF iNFraStruCture aND aDMiNiStrative SeCtor
Infrastructure and administrative resources appraisal was 
performed for the following categories of overhead: 1) real 
estate; 2) public utility services (water, electricity, tele-
phone, and other); 3) administrative personnel; 4) other 
supporting services (cleaning and security); 5) technical 
and administrative support equipment; and 6) stationery 
and other office supplies.
Estimates included the 15 outpatient clinics and one 
administrative headquarters within the program in the 
city of São Paulo.
Real estate was expressed as area occupied, according 
to information provided by the PMDASP. Public utility 
services consumed during 2006 were calculated according 
to invoice data. Human resources were calculated accord-
ing to the PMDASP payroll. Other supporting services 
were recorded through data in outsourcing contracts.
Technical and administrative support equipment were 
estimated according to basic infrastructure recommended 
for ambulatory assistance reported in a reference guide for 
healthcare services published by the Brazilian Ministry of 
Health. Compliance to recommendations was investigated 
by comparing references with the infrastructure observed 
in loco. Stationery and other office supplies were calculated 
according to invoices information.
In order to properly distribute the share of infrastruc-
ture and administrative resources among different health-
care services provided within the program, an applicable 
rate of overhead allocation factor was estimated based on 
global expenditures and number of patients in follow-up 
during 2006.
The program covered 16,789 HIV patients and 4,317 
STD patients in outpatient treatment in São Paulo during 
2006; a global cost of US$ 63,876,528.60 (figures converted 
into 2010 U.S. dollars), encompassing US$ 2,552,545.29 
(4.0%) for primary prevention and US$ 61,323,983.31 
(96.0%) for outpatient treatment. Expenditures on out-
patient treatment were distributed between HIV patients 
(86.9% of total cost) and other STDs patients (9.1% of total 
cost); the former rate was considered an appropriate over-
head allocation factor to determine the share of unspecific 
resources attributable to healthcare services performed for 
HIV outpatient treatment.
reSourCeS valuatioN
priceS reSearch
Data collection regarding prices included the valuation of 
resources registered as medical procedures and as infra-
structure/administrative sector.
Considering the resources required for medical pro-
cedures, prices for ARV drugs were collected from public 
databases on government purchases during 2006. Prices 
of vaccines, medications other than ARV, and inputs for 
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health procedures (e.g. therapy, counseling, medical con-
sultation, curatives, and other) were collected through 
market research at retail suppliers. Prices related to den-
tal services, diagnostics, and other exams were gathered 
from public databases on government fees for payment of 
private providers. Prices related to other inputs required 
(e.g. infant formula, condoms, and other) were obtained 
through market research at retail suppliers.
Considering resources required for infrastructure/
administrative sector, prices of public utility services 
consumed during 2006 were based on total expenditures 
registered in the invoices. Expenditures on supporting ser-
vices were gathered from the outsourcing contracts. Wages 
referring to human resources were obtained directly from 
the PMDASP payrolls. Prices of stationery and other office 
supplies were collected from the invoices.
Real estate was valued according to the opportunity 
cost of rental in the area occupied. Technical and adminis-
trative support equipment was valued according to market 
research conducted at retail suppliers. Obsolete equipment 
not found in market research was valued according to the 
inventory data from government accountancy systems 
provided by the Ministry of Health. Information on real 
estate and durable resource lifecycles was obtained from 
the Foundation Institute for Economic Research (Funda-
ção Instituto de Pesquisas Econômicas — FIPE), which is 
responsible for cost of living estimates in São Paulo, in or-
der to allow accounting for depreciation (corresponding 
to the amortization of the financial capital in each period, 
inversely related to resource lifecycle), maintenance (con-
sidered equivalent to depreciation), and daily opportunity 
costs due to financial operations in acquisition, using the 
official long-term interest rate for social programs from 
the Brazilian Development Bank (Banco Nacional de De-
senvolvimento Econômico e Social — BNDES).
coST eSTimaTeS
Cost calculation of HIV outpatient treatment for indi-
viduals with different CD4 cell counts within the Brazilian 
public program involved five stages:
1. Obtaining the cost of medical procedures per-
formed, multiplying the prices of inputs required 
by technical coefficients of inputs, and adding up 
medical procedures supplied to each patient during 
2006;
2. Obtaining the cost of services provided by admin-
istrative sector, multiplying the prices of inputs re-
quired annually by the overhead allocation factor 
and, subsequently, dividing by the HIV patients’ 
visits registered in 2006;
3. Obtaining the cost of services provided by infra-
structure, dividing the value of real estate or equip-
ment by estimated lifecycle. Annual cost of infra-
structure was multiplied by the overhead allocation 
factor and, subsequently, divided by HIV patients’ 
visits registered in 2006;
4. Annual costs attributable to the set of resources 
consumed in HIV outpatient treatment for each 
individual during 2006 were added and converted 
into U.S. dollars at the official exchange rate of De-
cember 29, 2006;
5. Accumulated inflation rate until 2010 was applied in 
order to provide actual figures in 2010 U.S. dollars, 
according to the Consumer Price Index reported by 
the Bureau of Labor Statistics.
Annual costs of HIV outpatient treatment from the 
Brazilian public program in São Paulo were stratified by 
CD4 cell count, considering major cost drivers according 
to categories. Literature research on studies analyzing the 
cost composition of HIV outpatient treatment in differ-
ent international health systems was performed, in order 
to undertake a comparison across countries, considering 
only studies conducted through similar methodology and 
costing techniques.
reSultS
Annual costs estimated for HIV outpatient treatment with-
in the Brazilian public program varied from US$ 1,726.19 
for patients with higher CD4 cell count to US$ 3,693.28 for 
patients with 51 < CD4 ≤ 200 (Table 1).
CD4 cell count
Brazilian costs
(95% CI)
Direct Relative
< 50 3,316.28 100.0% 2,172.40-4,460.17
51-200 3,693.28 111.4% 2,566.07-4,820.49
201-350 2,423.98 73.1% 1,923.73-2,924.24
351-500 2,244.17 67.7% 1,706.89-2,781.45
> 500 1,726.19 52.1% 1,421.50-2,030.87
Mean 2,572.92 77.6% 2,236.10-2,909.74
Table 1 – Annual and relative costs of HIV outpatient treatment of the Brazilian public program, according to CD4 strata. 
São Paulo, Brazil, 2006 (2010 USD)
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Patients with higher CD4 cell count had lower outpa-
tient costs, accounting for nearly half of treatment costs 
estimated for patients with lower CD4 cell count. HIV 
outpatient treatment costs declined slightly for individu-
als with CD4 cell count ≤ 50 due to the decrease in ARV 
costs. Nevertheless, such shift in the structure of costs 
within the Brazilian public program is compensated by 
an increase in costs due to other healthcare services (such 
as dental care) within the program.
There were no significant differences in costs of HIV 
outpatient treatment in relation to individuals’ gender 
and ethnicity. Regarding age group, average costs due 
to ARVs and exams were higher for younger individuals 
(Table 2).
Main cost drivers of HIV outpatient treatment in the 
Brazilian public program in São Paulo during 2006 were 
ARVs, medications other than ARV, health professional 
services, and diagnostic exams.
A significant proportion of HIV outpatient treat-
ment costs was associated to ARV utilization, ranging 
from 55.8% of the annual outpatient treatment costs for 
individuals with CD4 cell count ≤ 50 to 66.8% of the 
annual outpatient treatment costs for individuals with 
351 < CD4 ≤ 500.
Medications other than ARV represented 16.1% of the 
annual outpatient treatment costs for a typical HIV patient 
in the program, whereas the third cost category in terms 
of budgetary impact within the program was health pro-
fessional services (8.7%). The proportion of costs due to 
medications other than ARVs presented broad variation 
across CD4 cell count strata, because of opportunistic ill-
ness treatment.
The shift in cost composition within the Brazilian 
public program for individuals with CD4 cell count ≤ 50 
appears to be related to the lower consumption of health 
professional services in the case of patients in worst health 
condition. However, medications other than ARV take a 
higher priority among patients with CD4 cell count ≤ 50, 
probably due to opportunistic infections.
Literature research on HIV outpatient treatment costs 
for HAART retrieved seven studies reporting details of 
healthcare costs from different countries from the late 
1990’s until 2006-2007, based on micro-costing techniques 
using the public provider perspective16,17,19-21,30,34. One of 
the studies did not report ARV costs within HIV treat-
ment19, and one study failed to present detailed data on 
HIV outpatient treatment costs20 and therefore both were 
excluded from the cost composition comparison.
Table 2 – Annual costs of HIV outpatient treatment of the Brazilian public program in the major cost categories, according 
to demographic and epidemiologic characteristics. São Paulo, Brazil, 2006 (2010 USD)
n ARVs
Other 
medications
Health 
professionals
Diagnostic 
exams
Infrastructure
Other 
materials
Age
18-29 30 2,208.61 137.08 275.24 783.72 109.22 94.98
30-39 127 1,415.98 143.20 213.55 454.64 109.22 94.98
40-49 130 1,536.84 128.70 229.01 329.24 109.22 94.98
> 50 65 1,774.43 124.35 216.59 341.28 109.22 94.98
Ethnicity
White 187 1,478.89 142.91 220.49 394.30 109.22 94.98
Black 41 1,891.48 117.17 223.56 432.25 109.22 94.98
Mixed race 99 1,551.63 127.36 226.67 502.21 109.22 94.98
Other/missing 25 2,140.02 119.05 255.58 202.41 109.22 94.98
Gender
Female 136 1,351.84 139.86 226.86 462.60 109.22 94.98
Male 216 1,747.06 130.05 223.96 385.75 109.22 94.98
CD4 cell count
< 50 20 1,849.74 885.28 228.61 148.46 109.22 94.98
51-200 80 2,197.21 906.87 222.68 162.33 109.22 94.98
201-350 87 1,543.99 300.94 225.96 148.90 109.22 94.98
351-500 93 1,499.08 191.16 225.73 124.00 109.22 94.98
> 500 72 1,037.52 166.95 224.86 92.65 109.22 94.98
Mean 1,594.36 415.44 225.08 133.84 109.22 94.98
ARV, antiretrovirals.
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Cost drivers of HIV outpatient treatment in differ-
ent health systems presented a certain similarity regard-
ing the share attributable to main cost categories (ARVs, 
medications other than ARV, health professional ser-
vices, and exams). However, the cost composition of the 
Brazilian public program in São Paulo presented some 
differences in relation to other countries (Table 3).
Additionally, the costs of HIV outpatient treatment 
in public programs16,21,30,34 were considerably lower com-
pared to HIV outpatient treatment costs in private set-
tings for the same period17. Costs from the Brazilian pub-
lic program for HIV treatment in São Paulo during 2006 
were equivalent to 10% to 20% of the costs reported in 
the USA study.
dIScuSSIon
The results obtained regarding cost composition of HIV 
outpatient treatment from the Brazilian public program 
in São Paulo during 2006 match those of the litera-
ture16,17,21,30,34, which indicate that the main cost drivers 
in HIV outpatient treatment are, correspondingly: ARVs, 
other medications, health professional services, and diag-
nostic exams. Nevertheless, the magnitude of cost drivers 
varied among HIV outpatient treatment programs due to 
health system efficiency, which may be associated with 
health financing structure and scale.
In terms of HIV program financing, the Brazilian 
public program for HIV treatment resembles the pub-
lic financing scheme described in the Mexican study16, 
which provides publicly financed healthcare services for 
HIV outpatient treatment, while the treatment for HIV 
patients in the USA is usually based on private out-of-
pocket expenditures.
ARVs still represented a major part of HIV outpa-
tient treatment costs in the Brazilian public program, 
independently of CD4 cell count stratum. Although the 
Brazilian public program for HIV treatment is often 
discussed regarding ARV patents issues, a comparative 
study on ARV prices in Brazil and other low- to middle-
income countries showed higher ARV prices in Brazil, 
especially in the case of locally-produced generic ARVs. 
Furthermore, the study shows that contrary to trends 
worldwide, generic ARVs prices have been increasing in 
Brazil since 200325.
Considering that cost estimates may be subject to 
different methodologies, the cost comparison among 
healthcare services provided for HIV patients in different 
health systems was performed cautiously, in order to ac-
complish an adequate selection of studies that described 
in detail the costing techniques, estimation procedures, 
databases used, and perspective adopted.
According to Levy et al.35, less than 2% of coun-
try studies reporting costs of HIV treatment based on 
HAART provided “adequate data” or “useful estimates” 
to ensure “a meaningful statement about costs”. More-
over, there are evidences of significant discrepancies be-
tween model estimates and country specialists’ estimates 
on resource requirements for HIV care36.
Only five studies reporting details of HIV outpatient 
costs based on micro-costing techniques using public 
provider perspective were retrieved from the late 1990’s 
to 2006-200716,17,19-21,30,34. Other studies on HIV treatment 
costs were performed prior to HAART development, 
as properly summarized by Gebo et al.17. No study pre-
senting more recent data on HIV treatment costs was 
retrieved.
Country
Developing countries36 South Africa21 Haiti30 Mexico16* USA17* Brazil
Year 2006-2007 2006 2003-2004 1997-2001 2006 2006
Annual cost 894.08 1,002.05 1,251.33 5,336.13 16,553.10 2,572.92
ARVs 64.7% 47.0% 40.4% 87.4% 76.2% 62.0%
Other medications 3.3% – 4.0% 3.3% 13.9% 16.1%
Human resources 13.4% 16.0% 14.7% 2.1% 5.2% 8.7%
Diagnostic exams 5.8% 19.0% 21.0% 5.9% 3.6% 5.2%
Infrastructure 9.4% 19.0% 5.2% 1.4% – 4.2%
Other materials 3.4% – 14.7% – – 3.7%
Sample 45 sites 4 sites 1 site 11 sites 3 sites 5 sites
Settings Subsidized Public & NGO Subsidized Public Private Public
ARV, antiretrovirals; NGO, non-governamental organizations. *Based on weighted average of data presented in the studies.
Table 3 – Cost composition of HIV outpatient treatment in different countries using micro-costing techniques, from the 
public provider perspective (2010 USD)
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concluSIon
Although cost comparison across different countries may 
be subject to some problems, due to both social context of 
the health system and methodology adopted for the cost 
estimates, this study aimed to illustrate the similarities and 
divergences in cost composition of HIV outpatient treat-
ment provided in different national health systems, pre-
senting the main costs drivers associated to various health 
financing arrangements.
Public programs for universal HIV treatment, such 
as the Brazilian case, are widely recognized, but seldom 
analyzed in terms of economic costs. The few evidences 
available include government budgetary figures analysis 
through gross-costing technique5,31 or cost-effectiveness 
analysis based on ARV prescriptions at patient level32.
Additionally, the mortality rates due to HIV in São 
Paulo have been declining notably since the program was 
started in 1990’s, decreasing from 21.2 to 7.9 deaths per 
100,000 inhabitants during the period between 1991 and 
2007, according to data from MonitorAIDS, a system from 
the Brazilian Ministry of Health designed to monitor the 
AIDS epidemics. The situation poses a challenge regard-
ing strategies for public policy management in the health 
sector, in order to accomplish a balance between public fi-
nancing through taxation and healthcare provision for the 
population.
The present study was designed to comprise a primary 
tool for public policy evaluation, and its results may be a 
valuable source of information for HIV programs world-
wide. The main limitation of the analysis is the absence 
of cost estimates for HIV inpatient treatment. Addition-
ally, the representativeness of the sample was calculated 
to characterize a municipal branch of the Brazilian public 
program for HIV treatment located in São Paulo and thus 
some results may not be extrapolated to country level due 
to scaling effects.
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